These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24149465)

  • 1. Development of a peptide-based vaccine targeting TMPRSS2:ERG fusion-positive prostate cancer.
    Kissick HT; Sanda MG; Dunn LK; Arredouani MS
    Cancer Immunol Immunother; 2013 Dec; 62(12):1831-40. PubMed ID: 24149465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
    Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
    Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA-A2-restricted cytotoxic T lymphocyte epitopes from human hepsin as novel targets for prostate cancer immunotherapy.
    Guo J; Li G; Tang J; Cao XB; Zhou QY; Fan ZJ; Zhu B; Pan XH
    Scand J Immunol; 2013 Sep; 78(3):248-57. PubMed ID: 23721092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells.
    Smith HA; McNeel DG
    J Immunother; 2011 Oct; 34(8):569-80. PubMed ID: 21904219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells.
    Oh S; Terabe M; Pendleton CD; Bhattacharyya A; Bera TK; Epel M; Reiter Y; Phillips J; Linehan WM; Kasten-Sportes C; Pastan I; Berzofsky JA
    Cancer Res; 2004 Apr; 64(7):2610-8. PubMed ID: 15059918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of human leucocyte antigen (HLA)-A*0201-restricted cytotoxic T lymphocyte epitopes derived from HLA-DOβ as a novel target for multiple myeloma.
    Kang YJ; Zeng W; Song W; Reinhold B; Choi J; Brusic V; Yamashita T; Munshi A; Li C; Minvielle S; Anderson KC; Munshi N; Reinherz EL; Sasada T
    Br J Haematol; 2013 Nov; 163(3):343-51. PubMed ID: 24032635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells.
    Olson BM; McNeel DG
    Cancer Immunol Immunother; 2011 Jun; 60(6):781-92. PubMed ID: 21350948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The STEAP1(262-270) peptide encapsulated into PLGA microspheres elicits strong cytotoxic T cell immunity in HLA-A*0201 transgenic mice--A new approach to immunotherapy against prostate carcinoma.
    Herrmann VL; Wieland DE; Legler DF; Wittmann V; Groettrup M
    Prostate; 2016 Apr; 76(5):456-68. PubMed ID: 26715028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of prostate-specific G-protein coupled receptor as a tumor antigen recognized by CD8(+) T cells for cancer immunotherapy.
    Matsueda S; Wang M; Weng J; Li Y; Yin B; Zou J; Li Q; Zhao W; Peng W; Legras X; Loo C; Wang RF; Wang HY
    PLoS One; 2012; 7(9):e45756. PubMed ID: 23029225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2(+) patients with hormone-refractory prostate cancer.
    Matsueda S; Kobayashi K; Nonaka Y; Noguchi M; Itoh K; Harada M
    Cancer Immunol Immunother; 2004 Jun; 53(6):479-89. PubMed ID: 14634796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational Analysis of Gene Fusions Predicts Novel MHC Class I-Restricted T-Cell Epitopes and Immune Signatures in a Subset of Prostate Cancer.
    Kalina JL; Neilson DS; Lin YY; Hamilton PT; Comber AP; Loy EMH; Sahinalp SC; Collins CC; Hach F; Lum JJ
    Clin Cancer Res; 2017 Dec; 23(24):7596-7607. PubMed ID: 28954787
    [No Abstract]   [Full Text] [Related]  

  • 12. Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen.
    Lu J; Celis E
    Cancer Res; 2002 Oct; 62(20):5807-12. PubMed ID: 12384542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation.
    Chakraborty NG; Stevens RL; Mehrotra S; Laska E; Taxel P; Sporn JR; Schauer P; Albertsen PC
    Cancer Immunol Immunother; 2003 Aug; 52(8):497-505. PubMed ID: 12783216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen.
    Xue BH; Zhang Y; Sosman JA; Peace DJ
    Prostate; 1997 Feb; 30(2):73-8. PubMed ID: 9051144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
    Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN
    J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New epitope peptides derived from parathyroid hormone-related protein which have the capacity to induce prostate cancer-reactive cytotoxic T lymphocytes in HLA-A2+ prostate cancer patients.
    Yao A; Harada M; Matsueda S; Ishihara Y; Shomura H; Takao Y; Noguchi M; Matsuoka K; Hara I; Kamidono S; Itoh K
    Prostate; 2005 Feb; 62(3):233-42. PubMed ID: 15389794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes.
    Passoni L; Scardino A; Bertazzoli C; Gallo B; Coluccia AM; Lemonnier FA; Kosmatopoulos K; Gambacorti-Passerini C
    Blood; 2002 Mar; 99(6):2100-6. PubMed ID: 11877285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA-A2-restricted cytotoxic T lymphocyte epitopes from human heparanase as novel targets for broad-spectrum tumor immunotherapy.
    Chen T; Tang XD; Wan Y; Chen L; Yu ST; Xiong Z; Fang DC; Liang GP; Yang SM
    Neoplasia; 2008 Sep; 10(9):977-86. PubMed ID: 18714399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A modified HLA-A*0201-restricted CTL epitope from human oncoprotein (hPEBP4) induces more efficient antitumor responses.
    Sun W; Shi J; Wu J; Zhang J; Chen H; Li Y; Liu S; Wu Y; Tian Z; Cao X; Li N
    Cell Mol Immunol; 2018 Aug; 15(8):768-781. PubMed ID: 29375131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.
    Terasawa H; Tsang KY; Gulley J; Arlen P; Schlom J
    Clin Cancer Res; 2002 Jan; 8(1):41-53. PubMed ID: 11801539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.